✦ LIBER ✦

Interferon alfa-2b (IFN-A2B)/ribavirin compared to consensus interferon (CIFN)/ribavirin in treatment of chronic hepatitis C

✍ Scribed by M.H. Sjogren; K. Holtzmuller; R.W. Sjogren

Book ID: 118564577
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 130 KB
Volume: 34
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(01)81742-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

[655] PEG-IFN ALFA-2a PLUS RIBAVIRIN IS

[655] PEG-IFN ALFA-2a PLUS RIBAVIRIN IS SUPERIOR COMPARED TO HIGH DOSE CONSENSUS INTERFERON (CIFN) AND RIBAVIRIN IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C

✍ T. Witthoeft; M. Fuchs 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 128 KB

Peginterferon alfa-2b plus ribavirin com

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

✍ Michael P Manns; John G McHutchison; Stuart C Gordon; Vinod K Rustgi; Mitchell S 📂 Article 📅 2001 🏛 The Lancet 🌐 English ⚖ 110 KB

Cost effectiveness of ribavirin/interfer

Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C

✍ John B Wong; Gary L Davis; Stephen G Pauker 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 116 KB

Combination therapy with interferon alfa

Combination therapy with interferon alfa-2B, ribavirin, and amantadine in chronic hepatitis C non-responders to interferon and ribavirin

✍ Hemant Pande; Paul J Thuluvath; Salim A Jaffer; Joyce Maygers 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 28 KB

r-interferon alfa–2b/ribavirin combined

r-interferon alfa–2b/ribavirin combined therapy followed by low-dose r-Interferon alfa-2b in chronic hepatitis C interferon nonresponders

✍ A. Perasso; G. Testino; F. Ansaldi; V. Venturino; G.C. Icardi 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 30 KB 👁 2 views

Cost-effectiveness of interferon alfa 2b

Cost-effectiveness of interferon alfa 2b and ribavirin in the treatment of chronic hepatitis C

✍ W. Ray Kim; John J. Poterucha 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 34 KB 👁 2 views

In their paper in the November issue of HEPATOLOGY, Younossi et al. 1 may have overestimated the cost effectiveness of interferon-ribavirin treatment. This mainly stems from their failure to take into account the fact that patients who achieve sustained response are not homogenous with respect to th